- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02437617
Genomic Profiling Assay in Phase I
A Study Exploring the Use of the Foundation Medicine Genomic Profiling Assay in a Phase I Solid Tumor Patient Population
연구 개요
상세 설명
If you agree to take part in this study, your tumor tissue collected previously from surgery or a prior biopsy (archived tissue) will be used for genetic testing. Genetic testing looks at whether specific genes are changed (mutated) in the tumor.
The results of the genetic testing will be documented in your medical record. Your doctor may use the results of the genetic testing to help decide which treatment you will have. While awaiting results of the genomic profile assay, you may be enrolled in another treatment either at MD Anderson or near your home. This will be decided by your treating physician.
Your samples will be given a code number when they are sent for genetic testing to Foundation Medicine. No identifying information will be directly linked to your samples. Only the researcher in charge of sending all tissue for testing will have access to the code numbers and be able to link the samples to you. This is to allow medical data related to the samples to be updated as needed. Foundation Medicine will not be able to link this data to you.
Researchers will also review your medical history from before and following the collection of tissue, to learn if the use of genetic testing had any effect on the outcome of your treatment.
This is an investigational study.
Up to 300 participants will take part in this study. All will be enrolled at MD Anderson.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
Texas
-
Houston, Texas, 미국, 77030
- University of Texas MD Anderson Cancer Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria
- Patients with advanced cancer.
- Consent for use of archival tissue from primary or metastatic cancer diagnosis. Note: Patients may currently be enrolled in other investigational protocol including treatment protocols.
- Control Group #2 only: Control Group #2 will consist of 100 patients from MDACC/Phase I historical archives. Patients (cases no older than 2 years) will be selected based on clinical characteristics and genomic alterations similar to matched targeted therapy group.
- Patients may have received prior 'matched' therapies; however, at the time of enrollment, patients may not currently be on a known 'matched' therapy, and may not have received a 'matched' therapy as the last treatment if not receiving treatment at the time of consent.
- Patients who have a life expectancy of greater than 3 months.
Exclusion Criteria:
- Patients with advanced cancer who are NOT likely to meet the additional enrollment criteria in matched targeted therapy protocols or treatments.
- Patients who do not have archival tissue available.
- Patients are excluded if their last treatment before enrollment included a targeted agent matched to a genomic alteration in the patient's tumor.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: 보병대
- 시간 관점: 유망한
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
---|---|
Control Group #1
Participants who have had tumor molecular analysis performed with the similar clinical characteristics and genomic aberrations but who receive therapy not matched to their aberrations, or who have received results from Foundation Medicine that fail to demonstrate any molecular alteration.
|
Tumor tissue collected previously from surgery or a prior biopsy (archived tissue) used for genetic testing.
|
Control Group #2
Participants from historical archives of MD Anderson, no older than two years, who received therapy not matched to their aberrations and are matched not only on the basis of the clinical characteristics, but also, as much as possible, on the basis of genomic aberrations.
|
Tumor tissue collected previously from surgery or a prior biopsy (archived tissue) used for genetic testing.
|
Matched Targeted Therapy Group
Participants with tumor aberrations who received matched targeted therapy.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Response Rate
기간: 6 months
|
Response rate of each of the three cohorts (matched targeted therapy group, control group #1 and control group #2) calculated along with its 95% confidence interval.
Response rate defined as proportion of participants who experience complete response (CR) or partial response (PR).
Clinical response evaluated according to the RECIST 1.1.
|
6 months
|
공동 작업자 및 조사자
수사관
- 연구 의자: Funda Meric-Bernstam, MD, M.D. Anderson Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- PA12-0360
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
진행된 암에 대한 임상 시험
-
Töölö HospitalTurku University Hospital; Tampere University Hospital; Jyväskylä Central Hospital; Kymenlaakso...모병
-
Advanced Bionics완전한심한 청력 손실 | Advanced Bionics HiResolution™ Bionic Ear System의 성인 사용자미국
-
University of AlbertaArthritis Society Canada; Wrist Evaluation Canada (WECAN)모병관절염 | 관절 질환 | 근골격계 질환 | 외상 후; 관절염 | 손목 관절염 | 주상골 불유합 | Scapholunate Advanced Collapse | 손목 관절병증캐나다
-
Extremity Medical모병골관절염 | 염증성 관절염 | 손목 터널 증후군(CTS) | 외상 후 관절염 | SLAC(Scapholunate Advanced Collapse) | Scapholunate Crystalline Advanced Collapse(SCAC) | 주상골, 사다리꼴 및 사다리꼴 고급 붕괴(STTAC) | Kienbock의 성인병 | 방사형 부정합 | 척골 전좌 | 주상골 불유합 진행성 허탈(SNAC)미국
Tumor Tissue에 대한 임상 시험
-
M3 HealthIrmandade da Santa Casa de Misericordia de Sao Paulo아직 모집하지 않음
-
Tianjin Medical University Second Hospital알려지지 않은
-
J. Peter Rubin, MD완전한
-
NICHD Pelvic Floor Disorders NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); University of Pennsylvania 그리고 다른 협력자들모집하지 않고 적극적으로